Expanded Scientific Office Unifies
Scientific-Focused Teams, Facilitating Seamless Collaboration
Across Product Portfolio
Lennox Most Recently Led Regulatory, Medical
Affairs, Safety and Quality Teams, Plus Drove Product Innovation,
at Bayer Consumer Health
Previous Chief Scientific Officer,
Alison Ives, to Lead Newly Formed
Disruptive Growth Team
DUBLIN, Jan. 6, 2025
/PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global
provider of Consumer Self-Care Products, today announced the
expansion of its Chief Scientific Office by uniting and integrating
all global quality, pharmacovigilance, patient safety, regulatory
affairs and innovation teams, enhancing organizational agility and
scale. This expansion also further supports the Company's
consumer-led innovation pipeline.
To lead this expanded office, the Company has appointed
Abbie Lennox as Executive Vice
President and Chief Scientific Officer. Ms. Lennox is an
experienced consumer self-care leader with a successful track
record of driving regulatory excellence, product life cycle
management and new product innovation across well-known consumer
self-care portfolios.
President and CEO Patrick
Lockwood-Taylor commented, "Expanding our Chief Scientific
Office by bringing quality, regulatory and innovation excellence
under one umbrella is an important step in our evolution and
blueprint to build One Perrigo.
Abbie is the right person to lead this new coordinated effort,
drive new consumer-led innovation that consumers trust and advance
our consumer self-care vision."
Ms. Lennox joins Perrigo from Bayer where she served as
Executive Board Member and Chief Trust and Science Officer,
responsible for leading the regulatory, medical affairs, safety and
quality teams. She led multiple innovation launches – both product
and claim-based – across global product categories, including
cardio, digestive health, allergy, cough, cold, pain, dermatology,
women's health, VMS (Vitamins, Minerals and Supplements) and
Rx-to-OTC switches. Specifically, Ms. Lennox provided scientific
leadership for the U.S. Rx-to-OTC switch for Astepro®,
emphasizing consumer-centric claims supported by robust medical
insights. She also led the introduction of Rennie® Gum,
the first European OTC chewing gum for digestive health, by
navigating rigorous clinical and registration requirements while
prioritizing consumer experience. Prior to her time at Bayer, she
served in regulatory affairs leadership roles with Reckitt
Benckiser, where she advanced their regulatory approach to pipeline
delivery across multiple health and wellness brands. Ms. Lennox
holds a First Class BSc (Honors) degree in Biomedical Science and
Chemistry from De Montfort University.
"I am thrilled to join Perrigo at such an exciting time in the
Company's long history and share its unwavering commitment to
producing self-care products that meet or exceed the highest
quality standards," said Lennox. "I also look forward to working
together with my new colleagues to best drive Perrigo's deep
innovation pipeline to win in the self-care industry."
Alison Ives, who previously
served as Chief Scientific Officer, has been appointed to lead a
newly formed Disruptive Growth Team focused on identifying and
pursuing emerging growth opportunities through category disruption
and entering new markets. After successfully serving as Perrigo's
Chief Scientific Officer, along with more than 20 years of
experience in science-focused roles, Ms. Ives has deep expertise to
unlock emerging growth opportunities.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of
Consumer Self-Care Products and over-the-counter (OTC)
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Visit Perrigo online at
www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors—many of which are
beyond the Company's control--that may cause the actual results,
levels of activity, performance or achievements of the Company or
its industry to be materially different from those expressed or
implied by any forward-looking statements. Interested persons
are urged to consult the Company's filings with the United States
Securities and Exchange Commission, available at
https://investor.perrigo.com/sec-filings, for a discussion of the
Company's business and financial condition and certain material
trends, risks, uncertainties and other factors relating thereto,
including those discussed under "Risk Factors" in the Company's
Form 10-K for the year ended December 31, 2023, and subsequent
filings.
Perrigo Contact
Bradley Joseph, Vice President,
Global Investor Relations & Corporate
Communications, (269) 686-3373, E-mail:
bradley.joseph@perrigo.com
Nicholas Gallagher, Senior
Manager, Global Investor Relations & Corporate Communications,
(269) 686-3238, E-mail: nicholas.gallagher@perrigo.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-expands-its-scientific-office-appoints-abbie-lennox-as-executive-vice-president-and-chief-scientific-officer-302342939.html
SOURCE Perrigo Company plc